Injecting botulinum toxin into the  treatment of blepharospasm

Popescu, Marius; Popescu, Stella Ioana; Cernat, Corina; Boariu, Ana Maria; Călin, Edward; Vieru, Ana; Mușat, Ovidiu

doi:10.22336/rjo.2018.24

Cited by 5 publications

(4 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Blepharospasm (BSP) is a form of focal dystonia [ 31 , 32 ] that is characterized by involuntary and prolonged bilateral contraction of periorbital muscles, including orbicularis oculi (OOc), procerus, and corrugator [ 33 ]. Its estimated prevalence is 5 per 100,000 people [ 16 , 30 , 34 , 35 ]. Though it may start with increased blinking, it can progress to disabling closure of the eye due to involuntary contractions of OOc [ 36 ].…”

Section: Discussion Of Bont Use In Different Indicationsmentioning

confidence: 99%

See 1 more Smart Citation

Botulinum Toxin in Movement Disorders: An Update

Anandan

Jankovic

2021

Toxins

106

View full text Add to dashboard Cite

Since its initial approval in 1989 by the US Food and Drug Administration for the treatment of blepharospasm and other facial spasms, botulinum toxin (BoNT) has evolved into a therapeutic modality for a variety of neurological and non-neurological disorders. With respect to neurologic movement disorders, BoNT has been reported to be effective for the treatment of dystonia, bruxism, tremors, tics, myoclonus, restless legs syndrome, tardive dyskinesia, and a variety of symptoms associated with Parkinson’s disease. More recently, research with BoNT has expanded beyond its use as a powerful muscle relaxant and a peripherally active drug to its potential central nervous system applications in the treatment of neurodegenerative disorders. Although BoNT is the most potent biologic toxin, when it is administered by knowledgeable and experienced clinicians, it is one of the safest therapeutic agents in clinical use. The primary aim of this article is to provide an update on recent advances in BoNT research with a focus on novel applications in the treatment of movement disorders. This comprehensive review of the literature provides a critical review of evidence-based clinical trials and highlights recent innovative pilot studies.

show abstract

Section: Discussion Of Bont Use In Different Indicationsmentioning

confidence: 99%

“…This relatively long duration of action offers potential advantage over other formulations in that it may allow increasing the intervisit interval beyond the conventional 3–4 months. LanbotulinumtoxinA (Prosigne; Shanghai, China) is a new preparation of BoNTA marketed chiefly in Asia [ 16 , 17 ].…”

Section: Introductionmentioning

confidence: 99%

Botulinum Toxin in Movement Disorders: An Update

Anandan

Jankovic

2021

Toxins

106

View full text Add to dashboard Cite

show abstract

“…Blepharospasm is typically unresponsive to systemic medication. The preferred treatment is BoNT injections into the orbital, preseptal and pretarsal segments of the orbicularis oculi muscle (62,79). Only one open-label study has evaluated pretarsal BoNT injections in PSP.…”

Section: Managementmentioning

confidence: 99%

Best Practices in the Clinical Management of Progressive Supranuclear Palsy and Corticobasal Syndrome: A Consensus Statement of the CurePSP Centers of Care

et al. 2021

View full text Add to dashboard Cite

Progressive supranuclear palsy (PSP) and corticobasal syndrome (CBS; the most common phenotype of corticobasal degeneration) are tauopathies with a relentless course, usually starting in the mid-60s and leading to death after an average of 7 years. There is as yet no specific or disease-modifying treatment. Clinical deficits in PSP are numerous, involve the entire neuraxis, and present as several discrete phenotypes. They center on rigidity, bradykinesia, postural instability, gait freezing, supranuclear ocular motor impairment, dysarthria, dysphagia, incontinence, sleep disorders, frontal cognitive dysfunction, and a variety of behavioral changes. CBS presents with prominent and usually asymmetric dystonia, apraxia, myoclonus, pyramidal signs, and cortical sensory loss. The symptoms and deficits of PSP and CBS are amenable to a variety of treatment strategies but most physicians, including many neurologists, are reluctant to care for patients with these conditions because of unfamiliarity with their multiplicity of interacting symptoms and deficits. CurePSP, the organization devoted to support, research, and education for PSP and CBS, created its CurePSP Centers of Care network in North America in 2017 to improve patient access to clinical expertise and develop collaborations. The directors of the 25 centers have created this consensus document outlining best practices in the management of PSP and CBS. They formed a writing committee for each of 12 sub-topics. A 4-member Steering Committee collated and edited the contributions. The result was returned to the entire cohort of authors for further comments, which were considered for incorporation by the Steering Committee. The authors hope that this publication will serve as a convenient guide for all clinicians caring for patients with PSP and CBS and that it will improve care for patients with these devastating but manageable disorders.

show abstract

“…Botulinum toxin is a common treatment for correcting facial asymmetries, particularly in cases of hemifacial palsy in which BoNT-A injections on the contralateral side are an effective treatment [6]. Botulinum toxin acts by blocking acetylcholine in neuromuscular synaptic clefts [7].…”

Section: Discussionmentioning

confidence: 99%

Treatment of post-traumatic chin deformities using bilateral botulinum toxin injections

Park

et al. 2019

Arch Craniofac Surg

View full text Add to dashboard Cite

Post-traumatic hematoma formation is a common complication of contusion. If the hematoma is large enough to aspirate or drain, it can be treated quickly and appropriately. However, if the hematoma is small or concealed by local swelling, it may be overlooked and left untreated. In most cases, a hematoma will resolve following conservative treatment; however, associated infection or muscle fibrosis can occur. Herein, we present the case of a patient with a chin deformity caused by a post-traumatic hematoma. The deformity was treated using botulinum toxin and triamcinolone acetonide injections as minimally invasive treatments. The course of treatment was good.

show abstract

Injecting botulinum toxin into the treatment of blepharospasm

Cited by 5 publications

References 4 publications

Botulinum Toxin in Movement Disorders: An Update

Botulinum Toxin in Movement Disorders: An Update

Best Practices in the Clinical Management of Progressive Supranuclear Palsy and Corticobasal Syndrome: A Consensus Statement of the CurePSP Centers of Care

Treatment of post-traumatic chin deformities using bilateral botulinum toxin injections

Contact Info

Product

Resources

About